pd 98059 has been researched along with Carcinoma, Hepatocellular in 44 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After DEN-induced hepatocellular carcinoma (HCC) in rats showed increased phosphorylation of JNK1/2, p38, and ERK1/2, we next antagonized TGF-β1-induced phosphorylation of JNK1/2, p38, ERK1/2, Smad2/3 signaling in HepG2 cells using SP600125, SB203580, and PD98059, respectively." | 1.42 | MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells. ( Boye, A; He, S; Jiang, Y; Kan, H; Wu, C; Yang, X; Yang, Y, 2015) |
| "Human hepatocellular carcinoma (HCC) cell lines SMMC7721 and Huh7 were used." | 1.39 | Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. ( Ding, X; Dong, S; Gao, J; Ke, S; Kong, F; Kong, J; Sun, W; Wang, S; Zheng, L, 2013) |
| "TRAIL-induced apoptosis of hepatocellular carcinoma cells (HuH-7, Hep3B) was associated with lysosomal permeabilization, as demonstrated by redistribution of the lysosomal protease cathepsin B into the cytosol." | 1.34 | cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. ( Bronk, SF; Gores, GJ; Guicciardi, ME; Werneburg, NW, 2007) |
| "Overexpressing MHBs(t) in hepatoma cells enhanced TRAIL-induced apoptosis." | 1.34 | The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. ( Chen, YH; Cui, M; Du, J; Han, L; Liang, X; Liu, Y; Ma, C; Qu, Z; Sun, W; Sun, Z; Zhang, L; Zhang, Z, 2007) |
| "The human hepatocellular carcinoma (HCC)-derived cell line KYN-2 is thought to provide a good model for studying the molecular basis of invasion and metastasis of human HCC, because it often shows cell scattering in vitro and intrahepatic metastasis in vivo." | 1.33 | MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. ( Aoyagi, Y; Genda, T; Honma, N; Ichida, T; Matsuda, Y; Takamura, M; Yamagiwa, S, 2006) |
| "Human hepatocellular carcinoma (HCC) is associated with increased expression and activity of mitogen-activated protein kinase (MAPK) signaling intermediates (ie, MEK, ERK)." | 1.32 | Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. ( Schmidt, CM; Wang, Y; Wiesenauer, CA; Yip-Schneider, MT, 2004) |
| "Here we show that GHS-R is found in hepatoma cells." | 1.31 | Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. ( Chihara, K; Iida, K; Kaji, H; Kangawa, K; Kojima, M; Matsumoto, M; Murata, M; Okimura, Y; Sowa, H, 2002) |
| "HepG2 human hepatoma cells, which do not express alpha(1B)AR, were stably transfected with a rat alpha1B(AR) cDNA (TFG2 cells), in order to study the effects of maintained alpha(1B)AR expression on hepatoma cell proliferation." | 1.30 | Alpha-adrenergic inhibition of proliferation in HepG2 cells stably transfected with the alpha1B-adrenergic receptor through a p42MAPkinase/p21Cip1/WAF1-dependent pathway. ( Auer, KL; Dent, P; Fisher, PB; Gao, B; Kunos, G; Seth, P; Spector, MS; Tombes, RM, 1998) |
| "Treatment of human hepatoma (HepG2) and murine hepatoma (Hepa1c1c7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1." | 1.30 | Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. ( Der, CJ; Kong, AN; Lei, W; Mandlekar, S; Weber, MJ; Wu, J; Yu, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 27 (61.36) | 29.6817 |
| 2010's | 10 (22.73) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 2 |
| Zhou, M | 1 |
| Jin, X | 1 |
| Li, B | 1 |
| Wang, C | 1 |
| Zhang, Q | 1 |
| Liao, M | 1 |
| Hu, X | 1 |
| Yang, M | 1 |
| Chen, Z | 1 |
| Chen, L | 4 |
| Sun, B | 1 |
| Liu, D | 1 |
| He, Y | 1 |
| Qi, L | 1 |
| Li, G | 1 |
| Han, Z | 1 |
| Zhan, L | 1 |
| Zhang, S | 1 |
| Zhu, K | 1 |
| Luo, Y | 1 |
| Zhang, N | 1 |
| Guo, H | 1 |
| Dong, S | 1 |
| Kong, J | 2 |
| Kong, F | 1 |
| Gao, J | 1 |
| Ke, S | 1 |
| Wang, S | 1 |
| Ding, X | 1 |
| Sun, W | 3 |
| Zheng, L | 1 |
| Wang, JG | 1 |
| Zheng, XX | 1 |
| Zeng, GY | 1 |
| Zhou, YJ | 1 |
| Yuan, H | 1 |
| Boye, A | 1 |
| Kan, H | 1 |
| Wu, C | 1 |
| Jiang, Y | 1 |
| Yang, X | 2 |
| He, S | 1 |
| Yang, Y | 1 |
| Huang, P | 1 |
| Zhuang, B | 1 |
| Zhang, H | 1 |
| Yan, H | 1 |
| Xiao, Z | 1 |
| Li, W | 1 |
| Zhang, J | 1 |
| Tang, Q | 1 |
| Hu, K | 1 |
| Koeffler, HP | 1 |
| Yin, D | 1 |
| Hong, E | 1 |
| Lee, E | 1 |
| Kim, J | 1 |
| Kwon, D | 1 |
| Lim, Y | 1 |
| Charni, F | 1 |
| Friand, V | 1 |
| Haddad, O | 1 |
| Hlawaty, H | 1 |
| Martin, L | 1 |
| Vassy, R | 1 |
| Oudar, O | 1 |
| Gattegno, L | 1 |
| Charnaux, N | 1 |
| Sutton, A | 1 |
| Qin, X | 1 |
| Liu, C | 1 |
| Zhou, Y | 1 |
| Wang, G | 1 |
| Lu, JT | 1 |
| Zhao, WD | 1 |
| He, W | 1 |
| Wei, W | 1 |
| Zhou, L | 2 |
| Wang, DS | 1 |
| Li, QJ | 1 |
| Zhang, Y | 3 |
| Dou, KF | 1 |
| Xie, L | 1 |
| Zheng, Y | 1 |
| Li, X | 2 |
| Zhao, J | 1 |
| Chen, X | 2 |
| Zhou, J | 1 |
| Hai, O | 1 |
| Li, F | 1 |
| Wu, R | 1 |
| Duan, L | 1 |
| Ye, L | 1 |
| Wang, H | 1 |
| Weng, Y | 1 |
| Luo, J | 1 |
| Tang, M | 1 |
| Shi, Q | 1 |
| He, T | 1 |
| Seong, J | 1 |
| Kim, SH | 1 |
| Suh, CO | 1 |
| Wen-Sheng, W | 1 |
| Hirashima, Y | 1 |
| Tsuruzoe, K | 1 |
| Kodama, S | 1 |
| Igata, M | 1 |
| Toyonaga, T | 1 |
| Ueki, K | 1 |
| Kahn, CR | 1 |
| Araki, E | 1 |
| Wiesenauer, CA | 1 |
| Yip-Schneider, MT | 1 |
| Wang, Y | 1 |
| Schmidt, CM | 1 |
| Yim, S | 1 |
| Oh, M | 1 |
| Choi, SM | 1 |
| Park, H | 1 |
| Keeton, AB | 2 |
| Xu, J | 2 |
| Franklin, JL | 2 |
| Messina, JL | 2 |
| Izumi, T | 1 |
| Yamaguchi, M | 2 |
| Tsukada, Y | 2 |
| Tanaka, T | 1 |
| Miyazawa, K | 2 |
| Kitamura, N | 2 |
| Peyregne, VP | 1 |
| Kar, S | 1 |
| Ham, SW | 1 |
| Wang, M | 1 |
| Wang, Z | 1 |
| Carr, BI | 1 |
| Menschikowski, M | 1 |
| Hagelgans, A | 1 |
| Heyne, B | 1 |
| Hempel, U | 1 |
| Neumeister, V | 1 |
| Goez, P | 1 |
| Jaross, W | 1 |
| Siegert, G | 1 |
| Murata, T | 1 |
| Hijikata, M | 1 |
| Shimotohno, K | 1 |
| Li, YL | 1 |
| Chen, XY | 1 |
| Duan, FL | 1 |
| Venable, DY | 1 |
| Frank, SJ | 1 |
| Honma, N | 1 |
| Genda, T | 1 |
| Matsuda, Y | 1 |
| Yamagiwa, S | 1 |
| Takamura, M | 1 |
| Ichida, T | 1 |
| Aoyagi, Y | 1 |
| Puppala, D | 1 |
| Gairola, CG | 1 |
| Swanson, HI | 1 |
| Guicciardi, ME | 1 |
| Bronk, SF | 1 |
| Werneburg, NW | 1 |
| Gores, GJ | 1 |
| Liang, X | 1 |
| Du, J | 1 |
| Liu, Y | 1 |
| Cui, M | 1 |
| Ma, C | 1 |
| Han, L | 1 |
| Qu, Z | 1 |
| Zhang, Z | 1 |
| Sun, Z | 1 |
| Zhang, L | 1 |
| Chen, YH | 1 |
| Elbirt, KK | 1 |
| Whitmarsh, AJ | 1 |
| Davis, RJ | 1 |
| Bonkovsky, HL | 1 |
| Auer, KL | 1 |
| Spector, MS | 1 |
| Tombes, RM | 1 |
| Seth, P | 1 |
| Fisher, PB | 1 |
| Gao, B | 1 |
| Dent, P | 1 |
| Kunos, G | 1 |
| Banfi, C | 1 |
| Mussoni, L | 1 |
| Risé, P | 1 |
| Cattaneo, MG | 1 |
| Vicentini, L | 1 |
| Battaini, F | 1 |
| Galli, C | 1 |
| Tremoli, E | 1 |
| Yu, R | 1 |
| Lei, W | 1 |
| Mandlekar, S | 1 |
| Weber, MJ | 1 |
| Der, CJ | 1 |
| Wu, J | 1 |
| Kong, AN | 1 |
| Sipeki, S | 1 |
| Bander, E | 1 |
| Buday, L | 1 |
| Farkas, G | 1 |
| Bácsy, E | 1 |
| Ways, DK | 1 |
| Faragó, A | 1 |
| Baek, JH | 1 |
| Jang, JE | 1 |
| Kang, CM | 1 |
| Chung, HY | 1 |
| Kim, ND | 1 |
| Kim, KW | 1 |
| An, W | 1 |
| Tan, X | 1 |
| Gao, D | 1 |
| Dai, J | 1 |
| Desbois-Mouthon, C | 1 |
| Cadoret, A | 1 |
| Blivet-Van Eggelpoël, MJ | 1 |
| Bertrand, F | 1 |
| Cherqui, G | 1 |
| Perret, C | 1 |
| Capeau, J | 1 |
| Abe, K | 1 |
| Hirai, M | 1 |
| Mizuno, K | 1 |
| Higashi, N | 1 |
| Sekimoto, T | 1 |
| Miki, T | 1 |
| Hirano, T | 1 |
| Nakajima, K | 1 |
| Inagaki, S | 1 |
| Nijhara, R | 1 |
| Jana, SS | 1 |
| Goswami, SK | 1 |
| Rana, A | 1 |
| Majumdar, SS | 1 |
| Kumar, V | 1 |
| Sarkar, DP | 1 |
| Murata, M | 1 |
| Okimura, Y | 1 |
| Iida, K | 1 |
| Matsumoto, M | 1 |
| Sowa, H | 1 |
| Kaji, H | 1 |
| Kojima, M | 1 |
| Kangawa, K | 1 |
| Chihara, K | 1 |
| Abiru, S | 1 |
| Nakao, K | 1 |
| Ichikawa, T | 1 |
| Migita, K | 1 |
| Shigeno, M | 1 |
| Sakamoto, M | 1 |
| Ishikawa, H | 1 |
| Hamasaki, K | 1 |
| Nakata, K | 1 |
| Eguchi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
44 other studies available for pd 98059 and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.
Topics: Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Flavonoids; Fluorouracil; Gene | 2020 |
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease-Free | 2021 |
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Chromones; Disease Progress | 2013 |
Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Topics: Apigenin; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular | 2014 |
MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Diethylnitrosamine; Flavonoi | 2015 |
Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Elevated Pressure Enhanced Trail-Induced Apoptosis in Hepatocellular Carcinoma Cells Via Erk1/2-Inactivation.
Topics: Apoptosis; bcl-Associated Death Protein; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cycl | 2015 |
Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.
Topics: Anthracenes; Antibodies, Monoclonal; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2009 |
Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7-1 Antigen; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2010 |
Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway.
Topics: Adult; Aged; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Moveme | 2012 |
Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Ki | 2012 |
Enhanced proliferation of human hepatoma cells by PAR-2 agonists via the ERK/AP-1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Extracellul | 2012 |
S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway.
Topics: Animals; Calgranulin B; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transf | 2013 |
Enhancement of radioresponse of murine tumors by ERK inhibitor.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Combined Modality Therapy; Enzyme Inhi | 2002 |
ERK signaling pathway is involved in p15INK4b/p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a.
Topics: Activating Transcription Factor 2; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Division; Cy | 2003 |
Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Chromones; Cycloheximide; Depression, Chemical; Enzym | 2003 |
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
Topics: Apoptosis; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Count; Cell Division; Cell | 2004 |
Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; DNA; Dose-Response Re | 2004 |
Regulation of Gene33 expression by insulin requires MEK-ERK activation.
Topics: Adaptor Proteins, Signal Transducing; Androstadienes; Animals; Carcinoma, Hepatocellular; Carrier Pr | 2004 |
Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 98059, dibucaine, or Bay K 8644.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2004 |
Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Ce | 2004 |
Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Topics: Antineoplastic Agents; Biotinylation; Blotting, Western; Breast Neoplasms; Carcinoma, Hepatocellular | 2005 |
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
Topics: Amides; Aorta; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Butadienes; Carcinoma, Hepatocell | 2005 |
Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059.
Topics: Base Sequence; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Hepatocellular; Cell Line, T | 2005 |
[The sensitivity improvement of HBx+HepG2 to CDDP with PD98059].
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Synergism; Flavonoids; Humans; Liver Neoplasms; Trans-Act | 2005 |
Insulin enhances growth hormone induction of the MEK/ERK signaling pathway.
Topics: Animals; Biological Transport; Carcinoma, Hepatocellular; Cattle; Cell Line, Tumor; Cell Proliferati | 2006 |
MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells.
Topics: Actin Cytoskeleton; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Culture Techniques; Ce | 2006 |
Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation.
Topics: Anticarcinogenic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Transformation, Neoplasti | 2007 |
cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis.
Topics: Apoptosis; Butadienes; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; | 2007 |
The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Enzyme Activation; Enzyme | 2007 |
Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases.
Topics: Animals; Arsenites; Cadmium; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Hepatocellular | 1998 |
Alpha-adrenergic inhibition of proliferation in HepG2 cells stably transfected with the alpha1B-adrenergic receptor through a p42MAPkinase/p21Cip1/WAF1-dependent pathway.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Carcinoma, Hepatocellul | 1998 |
Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells.
Topics: Antioxidants; Arachidonic Acid; Calcium Channel Blockers; Calcium-Calmodulin-Dependent Protein Kinas | 1999 |
Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Induction; Enzyme Inhibitors; Flav | 1999 |
Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering.
Topics: Carcinoma, Hepatocellular; Cell Movement; Chromones; Cycloheximide; Enzyme Inhibitors; Flavonoids; H | 1999 |
Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis.
Topics: Apoptosis; Autocrine Communication; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3 | 2000 |
Phosphorylation of hepatic stimulator substance on mitogen-activated protein kinase in BEL-7402 hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; ErbB Receptors; Flavonoids; Growth Substances; Intercellular Sig | 2001 |
Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation.
Topics: beta Catenin; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Hepatocellular; Cell Division | 2001 |
The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3T3 Cells; Alanine; Amino Acid Sequence; Amino Acid S | 2001 |
Regulatory role of endogenous regucalcin in the enhancement of nuclear deoxyribonuleic acid synthesis with proliferation of cloned rat hepatoma cells (H4-II-E).
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |
High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; DNA Primers; Enzyme Inhibitors; | 2001 |
Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.
Topics: Animals; Carcinoma, Hepatocellular; DNA, Viral; Enzyme Activation; Female; Flavonoids; Hepatocytes; | 2001 |
Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cells, Cultured; Cu | 2002 |
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cyclooxygenase 2; Cyclo | 2002 |